Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

James, 2015, Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019), Eur Urol, 67, 1028, 10.1016/j.eururo.2014.09.032 Beer, 2017, Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study, Eur Urol, 71, 151, 10.1016/j.eururo.2016.07.032 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755 de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X Ryan, 2015, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 16, 152, 10.1016/S1470-2045(14)71205-7 Ghosh, 2004, Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer, J Cell Biochem, 91, 528, 10.1002/jcb.10661 Perera, 2016, Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis, Eur Urol, 70, 926, 10.1016/j.eururo.2016.06.021 Rahbar, 2017, German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients, J Nucl Med, 58, 85, 10.2967/jnumed.116.183194 Kulkarni, 2016, PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013, J Nucl Med, 57, 97S, 10.2967/jnumed.115.170167 Yadav, 2017, 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment, Eur J Nucl Med Mol Imaging, 44, 81, 10.1007/s00259-016-3481-7 Kratochwil, 2016, PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617, J Nucl Med, 57, 1170, 10.2967/jnumed.115.171397 Rahbar, 2016, Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer, Clin Nucl Med, 41, 522, 10.1097/RLU.0000000000001240 Ahmadzadehfar, 2015, Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study, EJNMMI Res, 5, 114, 10.1186/s13550-015-0114-2 Baum, 2016, 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy, J Nucl Med, 57, 1006, 10.2967/jnumed.115.168443 Heck, 2016, Systemic radioligand therapy with 177Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer, J Urol, 196, 382, 10.1016/j.juro.2016.02.2969 Fendler, 2017, Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer, Oncotarget, 8, 3581, 10.18632/oncotarget.12240 Ahmadzadehfar, 2016, Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer, Oncotarget, 7, 12477, 10.18632/oncotarget.7245 Rahbar, 2016, Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis, J Nucl Med, 57, 1334, 10.2967/jnumed.116.173757 Ahmadzadehfar, 2017, Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617, Eur J Nucl Med Mol Imaging, 44, 1448, 10.1007/s00259-017-3716-2 Brauer, 2017, 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer, Eur J Nucl Med Mol Imaging, 44, 1663, 10.1007/s00259-017-3751-z Rahbar, 2018, PSMA targeted radioligand therapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival, Eur J Nucl Med Mol Imaging, 45, 12, 10.1007/s00259-017-3848-4 Hofman, 2018, [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study, Lancet Oncol, 19, 825, 10.1016/S1470-2045(18)30198-0 Violet JA, Jackson P, Ferdinandus J, et al. Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and “whole body” tumor dosimetry with treatment outcomes. J Nucl Med. In press. https://doi.org/10.2967/jnumed.118.219352. Sandhu, 2018, Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): interim results of a phase II trial, J Clin Oncol, 36, 5040, 10.1200/JCO.2018.36.15_suppl.5040 Schoder, 2005, 2-[18F]Fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy, Clin Cancer Res, 11, 4761, 10.1158/1078-0432.CCR-05-0249 Jadvar, 2013, Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations, Eur J Nucl Med Mol Imaging, 40, S5, 10.1007/s00259-013-2361-7 Jadvar, 2013, Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer, J Nucl Med, 54, 1195, 10.2967/jnumed.112.114116 Jadvar, 2016, Is there use for FDG-PET in prostate cancer?, Semin Nucl Med, 46, 502, 10.1053/j.semnuclmed.2016.07.004 Fox, 2018, Positron emission tomography/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer, JAMA Oncol, 4, 217, 10.1001/jamaoncol.2017.3588 Tesson, 2016, Preliminary evaluation of prostate-targeted radiotherapy using 131I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs, J Pharm Pharmacol, 68, 912, 10.1111/jphp.12558